Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20755614 | 0.89 | TRPA1 (0.33) | TRPA1TRPM8 | |
| SCHEMBL18523230 | 0.84 | TRPA1 (0.32) | TRPA1TRPM8 | |
| SCHEMBL21188034 | 0.83 | TRPA1 (0.31) | TRPA1TRPM8 | |
| SCHEMBL24267942 | 0.83 | TRPA1 (0.31) | TRPA1TRPM8 | |
| SCHEMBL21744770 | 0.83 | TRPA1 (0.31) | TRPA1TRPM8 | |
| SCHEMBL25091193 | 0.83 | TRPA1 (0.31) | TRPA1TRPM8 | |
| SCHEMBL24267777 | 0.83 | TRPA1 (0.31) | TRPA1TRPM8 | |
| SCHEMBL9920196 | 0.83 | TRPA1 (0.31) | TRPA1TRPM8 | |
| SCHEMBL20676098 | 0.83 | TRPA1 (0.31) | TRPA1TRPM8 | |
| SCHEMBL19122839 | 0.83 | TRPA1 (0.31) | TRPA1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10835623-B2 | Manganese-based chelate conjugates for molecular MR imaging | THE GENERAL HOSPITAL CORPORATION (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2019036384-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190001003-A1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | THE GENERAL HOSPITAL CORPORATION | 2019-01-03 | — | — | US | disclosed |
| WO-2017027834-A1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | TRPA1 4401/4885TRPM8 3930/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | TRPA1 4401/4885TRPM8 3930/4885 |
| US-20190001003-A1 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | MPI, MAG, MNS1 | TRPA1 4392/4885TRPM8 1260/4885 |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | TRPA1 4332/4885TRPM8 4067/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | TRPA1 4332/4885TRPM8 4067/4885 |
| US-10835623-B2 | Manganese-based chelate conjugates for molecular MR imaging | MPI, MAG, MNS1 | TRPA1 4392/4885TRPM8 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.